Answers are grounded in this paper and cite their sources.
Radiotherapy (RT) is a cornerstone of cancer treatment, but its efficacy is often limited by tumor radioresistance arising from DNA damage repair, redox buffering, metabolic adaptation, cell-cycle regulation, hypoxia, and insufficient intratumoral radiation energy deposition. These barriers reduce direct tumor killing and limit the ability of RT to generate systemic antitumor immune responses. Nanoparticle-based radiosensitizers offer a promising strategy for overcoming these limitations. These nanoradiosensitizers can enhance local radiation absorption, amplify reactive oxygen species generation, disrupt antioxidant defenses, inhibit DNA repair, remodel the tumor microenvironment, and regulate radiation-induced cell death. Through these coordinated mechanisms, nanoradiosensitizers can convert sublethal radiation injury into more effective tumor destruction. Importantly, nanoradiosensitizers can also reshape the immune consequences of RT by promoting immunogenic cell death, antigen release, innate immune activation, and relief of tumor immunosuppression. In this Review, we summarize key mechanisms of tumor radioresistance, highlight recent advances in nanoradiosensitizers for enhancing RT and antitumor immunity, and discuss major challenges for their clinical translation.
No takes yet. Share an insight, caveat, or question.
Song et al. (2026) studied this question.